Germany Blood Glucose Monitoring System Market Insight
Published: 24 June 2026 | Report Format: Electronic (PDF) | Author: Govind and Krishna
The high prevalence of diabetes, technological improvements, robust healthcare infrastructure that facilitates the use of advanced monitoring equipment, blood glucose monitoring market in Germany is expected to rise at 7.02% CAGR.
Germany Blood Glucose Monitoring System Market Insights Forecasts to 2035
- The Germany Blood Glucose Monitoring System Market Size Was Estimated USD 755.5 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 7.02% from 2025 to 2035
- The Germany Blood Glucose Monitoring System Market Size is Expected to rise around USD 1488.7 Million by 2035
Notable Insights for the Germany Blood Glucose Monitoring System Market
- Based on product segmentation, the fastest-growing segment in Germany is Continuous Glucose Monitoring systems, while Self-Monitoring Blood Glucose systems lead in revenue.
- Based on end-user segmentation, hospitals and clinics are important channels for high-end CGM systems, but home care settings consume the majority of test strips.
- Through the early forecast years, the market maintains an annual test strip consumption of 2.3 billion units, with an anticipated 11 million people in Germany having been diagnosed with diabetes.
- The diabetes device market in Germany is expected to expand significantly from $1.39 billion in 2023 to $2.62 billion by 2032.
Download the eBook (ToC)
Why Buy This Report
- Learn everything there is to know about the blood glucose monitoring system market in Germany, including its size, growth projections, new trends, competitive environment, technological advancements, and changing demand in various healthcare settings.
- In order to make well-informed strategy planning, investment decisions, and long-term business expansion within Germany's diabetes care sector, it is necessary to comprehend the major market drivers, constraints, opportunities, and challenges driving industry growth.
- To find high-growth sectors and improve product development and market entry tactics, thoroughly analyze segmentation by product kind, monitoring technique, end user, distribution channel, and region.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Germany blood glucose monitoring system market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in Germany Blood Glucose Monitoring System Market
- Roche Diabetes Care
- Abbott Laboratories
- Ascensia Diabetes Care
- Dexcom, Inc.
- Medtronic
- LifeScan (OneTouch)
- Beurer
- GlucoRx
- Novo Nordisk A/S
- Sanofi
Recent Developments:
- In March 2024, patients with Type 2 diabetes' access to its CONTOUR blood glucose monitoring systems, Ascensia Diabetes Care established a partnership with a top German health insurer.
- In February 2024, Dexcom introduced their Dexcom ONE+ real-time CGM system, which gives consumers a more cost-effective choice with three body positioning options for improved comfort.
Market Segmentation:
Germany Blood Glucose Monitoring System Market, By Product Type
- Self-Monitoring Systems (Blood Glucose Meters, Test Strips)
- Continuous Blood Glucose Monitoring Systems (Sensors, Transmitters)
Germany Blood Glucose Monitoring System Market, By Testing Site
- Fingertip
- Alternate Site (e.g., forearm, palm)
Germany Blood Glucose Monitoring System Market, By End-User
- Self/Home Care
- Hospitals
- Clinics
Expert Views:
The structure of the German glucose monitoring market is experiencing a transformation. Although SMBG continues to be used by most diabetic patients, the uptake of CGM is lowering the use of strips. Roche and Ascensia lead the conventional category. Strict EU IVDR requirements slow down product launches and foster consolidation. Adoption of new devices depends increasingly on connectivity.
Author: Govind and Krishna By Decisions Advisors and Consulting